THE 2019 20TH ANNUAL PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS CONTENT IS NOW AVAILABLE IN VARIOUS POST CONFERENCE FORMATS
PHARMA CONGRESS CONTENT AS FOLLOWS:
Complete conference: $195
$195
FEATURING INVITATION-ONLY:
CHIEF COMPLIANCE OFFICER ROUNDTABLE
(Jointly Sponsored by PCF and PhRMA; Special November 6 Morning Session, Invitation-only)
FEATURING
Sally Molloy, JD
Chief, Strategy, Policy & Training Unit, Fraud Section, Former Assistant U.S. Attorney, US Attorney’s Office, Northern District of Georgia, US Department of Justice, Washington, DC
KEYNOTE SPEAKERS
Thomas W. Abrams, RPh, MBA
Director, Office of Prescription Drug Promotion, US Food and Drug Administration, Silver Spring, MD
Brian Allen Benczkowski, JD
Assistant Attorney General, Criminal Division, US Department of Justice; Former Principal Deputy Assistant Attorney General for Legislative Affairs; Former Republican Staff Director, Committee on the Judiciary, US Senate; Former Staff, Senator Pete Domenici and Representative Jim Sensenbrenner, Washington, DC
Alexandra Christina, Countess of Frederiksborg
Member, Board of Directors – Chairperson Ethics and Compliance Board Committee, Ferring Pharmaceuticals, Co-author, The Sincerity Edge, Former Poling Chair of Business and Government, Kelley School of Business, Indiana University, Copenhagen, Denmark
Susan Dentzer
Visiting Fellow, Duke-Margolis Center for Health Policy, Former Editor in Chief, Health Affairs, Former Health Correspondent, PBS NewsHour, Washington, DC
Mary E. Riordan, JD
Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, Washington, DC
A KEYNOTE PANEL ON LESSONS LEARNED FROM
20 YEARS OF PHARMA & DEVICE INVESTIGATIONS,
PROSECUTIONS, ETHICS & COMPLIANCE WITH
Douglas M. Lankler, JD
Executive Vice President, General Counsel, Pfizer, Former Assistant US Attorney, Southern District of New York, US Department of Justice, New York, NY
Daniel Ronald Levinson, JD
Former Inspector General, US Department of Health and Human Services, Former Inspector General, US General Services Administration, Former Chairman, US Merit Systems Protection Board, Former General Counsel, US Consumer Product Safety Commission, Washington, DC
Lori Queisser
Senior Vice President and Global Chief Compliance Officer, Teva Pharmaceuticals; Former Sr. VP Global Compliance and Business Practices; Schering-Plough Corporation; Former Vice President, Chief Compliance Officer, Eli Lilly; Former Member, PCF Executive Committee, Horsham, PA
Arjun Rajaratnam, JD, MS
Chief Compliance Officer, Smith & Nephew; Former Compliance Officer, US Pharmaceuticals, GlaxoSmithKline; Former Member, PCF Executive Committee; Raleigh, NC
James Sheehan, JD
Chief, Charities Bureau at Attorney General of New York, Former Chief Integrity Officer, Executive Deputy Commissioner, City of New York Human Resources Administration, Former NY Medicaid Inspector General, Former Associate United States Attorney, US Attorney’s Office for the Eastern District of Pennsylvania, New York, NY
Susan Winkler, JD, MA
Founder, Winkler Law LLC; Former Assistant US Attorney and Head, Health Care Fraud Unit, US Attorney’s Office for the District of Massachusetts, Boston, MA
Kris Curry, MBA
Principal, Assurance Services, EY, Former Vice President, Global Chief Compliance Officer, Pharma Sector, Johnson & Johnson, Philadelphia, PA (Moderator)
THE ANNUAL CCO ROUNDTABLE WITH
Charlene E. Davis, JD
Vice President & Chief Compliance Officer, Aerie Pharmaceuticals, Inc.; Former Senior Compliance Counsel and Senior Director, Corporate Compliance and Compliance Operations, Otsuka Pharmaceutical, Princeton, NJ
Adam Dubow, JD
Global Chief Compliance and Ethics Officer, Bristol-Myers Squibb, Princeton, NJ
Keith Korenchuk, MPH, JD
VP and Chief Compliance Officer Danaher Diagnostics and Beckman Coulter Diagnostics, DANAHER Corporation; Former Partner, Arnold & Porter Kaye Scholer; Chevy Chase, MD
Dominique Laymand, JD
Executive Vice President, Chief Ethics and Compliance Officer, Ipsen; Honorary President, International Society of Healthcare Ethics and Compliance Professionals (ETHICS), Paris, France
Sunitha Ramamurthy, JD
Head of Compliance, Loxo Oncology, wholly owned subsidiary of Eli Lilly; Former Executive Director, Office of Ethics and Compliance, Boehringer Ingelheim Pharmaceuticals; Stamford, CT
Thomas J. Schumacher, JD
Vice President and Global Chief, Ethics and Compliance Officer, Medtronic, Fridley, MN
Paul Silver
Principal, Regulatory & Compliance Life Sciences Leader, Deloitte Advisory, Deloitte, Atlanta, GA (Moderator)
THE ANNUAL DOJ AND SEC FCPA
ENFORCEMENT UPDATE WITH
Robert I. Dodge, JD
Assistant Director, FCPA Unit, US Securities & Exchange Commission, Former Assistant U.S. Attorney, US Attorney’s Office, Western District of Michigan, Former Assistant Section Chief, Environmental Defense Section, US Department of Justice, Washington, DC
David Last, JD
Assistant Chief, FCPA Unit, Fraud Section, Criminal Division, US Department of Justice, Washington, DC
Gary F. Giampetruzzi, JD
Partner, Paul Hastings; Former Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc.; New York, NY (Moderator)
THE ANNUAL AUSA ROUNDTABLE WITH
John Claud, JD
Assistant Director, Consumer Protection Branch, US Department of Justice, Washington, DC
Rachael A. Honig, JD
First Assistant U.S. Attorney, U.S. Attorney’s Office, District of New Jersey, US Department of Justice; Former Corporate Counsel, Litigation, Celgene; Newark, NJ
Amanda Masselam Strachan, JD
Assistant US Attorney and Chief, Health Care Fraud Unit, US Attorney’s Office, District of Massachusetts, US Department of Justice, Boston, MA
John T. Bentivoglio, JD
Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud, and Chief Privacy Officer, US Department of Justice; Washington, DC (Moderator)
AND A FRIDAY, NOVEMBER 8 INDUSTRY-ONLY
BEST PRACTICES ROUNDTABLE
(Industry-only session for pharma and medical device compliance
professionals and in-house counsel only)
FEATURING
Jacob T. Elberg, JD
Associate Professor of Law, Seton Hall Law School, Former Chief, Health Care & Government
Fraud Unit and Assistant US Attorney, US Attorney’s Office, District of New Jersey, US
Department of Justice, Newark, NJ
AGENDA AT A GLANCE
WEDNESDAY, NOVEMBER 6
AN INVITATION-ONLY CCO ROUNDTABLE
PRECONFERENCE SESSIONS:
— Third Party Interactions, Including Distributors and Non-Distributor 3rd Party Vendor Compliance (begins at 10:00 am)
— Investigations: Interconnectivity of Auditing, Monitoring, and Investigations, Including Privilege
— Emerging Role of Analytics, Big Data & AI Opportunities for Life Sciences…
OPENING PLENARY SESSION:
— 20th Anniversary Dialogue: Lessons Learned
— Keynote: OIG Update
— US DOJ Keynote
— FDA Keynote
— What Pharma/Medical Device Industries Can Learn from the Opioid Cases
— Annual Chief Compliance Officer Roundtable
THURSDAY, NOVEMBER 7
BREAKFAST WORKSHOPS:
— HCP Contracting—Benchmarking and Lessons Learned…
— Navigating Drug Price Transparency Laws…
MORNING PLENARY SESSION:
— Keynote by Alexandra Christina, Countess of Frederiksborg
— US DOJ and US SEC Update on FCPA Enforcement
— AUSA Roundtable
MINI SUMMITS
— Reduce Compliance Risk Using a “Portfolio” Approach to Training! (Microlearning Alone is Not the Answer)
— Setting Your Five-Year Strategic Compliance Plan
— Interactions with Patients Including Benchmarking on Patient Services Compliance
— Enhanced Compliance Monitoring
— Best Practices Calculating Profit Disgorgement in Preparation for Compliance Settlements
— Annual Medical Device Roundtable
— Lessons Learned from Enforcement Actions
— Compliance Program Operations: Building Effective and Right Sized Compliance Programs
— Value-Based Arrangements
— Challenges and/or Considerations When Performing a Fair Market Value (FMV) Analysis
— Patient Support Programs – Helping Patients Access Products
— Issues with Medical Device/Combination Products
— Charitable Contributions Compliance Considerations
— How do you Modernize your Compliance Program to Prepare for the Future of Health?
— Medical Affairs Proactive Communications, Engagement by Manufacturers
— HCP Engagement and Transparency Perspectives
— Compliance – Board Communications: Effective Measurement and Reporting Strategies
— Best Practices when Transitioning from Healthcare Compliance Risk to Enterprise Risk Assessments
— Medical Device Asset Management Risk Considerations
— Responding to CCPA, GDPR and the Tumultuous World of Data Privacy
— Social Media Engagement by Manufacturers
— Conducting R&D Compliance Risk Assessments
— Ensuring a Smooth Transition of Compliance Programs During Mergers & Acquisitions
— Investigations: Properly Executing a Compliance Investigation Initiated by a Whistleblower
— Compliance Interactions with Specialty Pharmacies
— Practice Development Programs (e.g., Free or Discounted Marketing Services)
CLOSING PLENARY SESSION
— The Changing Face of the Qui Tam